2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive use
2023
Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. Journal Of Vascular And Interventional Radiology 2023, 34: 1997-2005.e3. PMID: 37468093, DOI: 10.1016/j.jvir.2023.07.010.Peer-Reviewed Original ResearchConceptsLiver transplantSurgical resectionHepatocellular carcinomaLT cohortBiliary injuryReadmission ratesAbscess formationIntensive care unit-level careLess healthcare utilizationNationally Representative CohortInitial hospital stayICU-level careAdverse event ratesEnd Results ProgramSmall hepatocellular carcinomaCare delivery outcomesFisher's exact testHealthcare Common Procedure Coding SystemChi-square testLow-intensity careLiver cancer treatmentPostprocedural hemorrhageHospital stayAdverse eventsSecondary outcomes